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ABSTRACT
Objective: The objectives of this study were to evaluate the effects of Vitamin K use for bleeding or coagulopathies prevention and to assess the 
occurrence of drug-related problems in patients receiving cefoperazone/sulbactam.
Methods: The prospective study was conducted between January and April 2018 at 5 general medicine wards in Mahasarakham Hospital, Thailand. 
Patients above 18 years of age with bacterial infections who received cefoperazone/sulbactam concurrent with Vitamin K were included. Rate of 
bleeding, coagulopathies, and drug-related problems were evaluated.
Results: Forty-three eligible patients enrolled in this study. Most were women (72.1%), average ages were 64.7 years old and 93.0% had comorbidities 
(most were diabetes, hypertension, and chronic kidney disease). High doses of cefoperazone/sulbactam have been used in 35 patients (81.4%). 
Gastrointestinal bleeding occurred in one patient (8.3%), 24 patients had prolonged prothrombin time (55.8%), and 8 patients had prolonged 
activated partial thromboplastin time (18.6%). Anticipated risk factors were not associated with bleeding. Drug-related problems were missing of 
dose adjustment for cefoperazone/sulbactam in patients with renal impairment (4.7%), drug interactions between warfarin and Vitamin K (4.7%), 
and drug allergy (2.3%).
Conclusion: This study found that cefoperazone/sulbactam aggravated bleeding and coagulopathies despite using Vitamin K for prevention. We 
support the use of Vitamin K for the prevention of bleeding in high-risk patient such as elderly who receive cefoperazone/sulbactam.
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INTRODUCTION
Cefoperazone is a beta-lactam antibiotic containing 
N-methylthiotetrazole side chain which may aggravate 
hypoprothrombinemia and bleeding by inhibiting hepatic Vitamin 
K epoxide reductase [1]. This medication is available in Thailand as 
combination with sulbactam; a beta-lactamase inhibitor. Previous 
study reported the use of cefoperazone in patients with bacterial 
infections caused prolonged prothrombin time 3.6 times compared 
to ceftizoxime and ceftazidime [2]. The use of Vitamin K for the 
prevention of bleeding or hypoprothrombinemia in patients receiving 
cefoperazone is controversy [3,4]. This study was performed to 
evaluate the effects of Vitamin K use for bleeding prevention and 
to assess the occurrence and character of drug-related problems 
in patients receiving cefoperazone/sulbactam at general medicine 
wards, Mahasarakham Hospital, Thailand.
METHODS
The prospective study was conducted between January and April 2018 
at 5 general medicine wards in Mahasarakham Hospital, Thailand. 
Patients above 18 years of age with bacterial infections who received 
cefoperazone/sulbactam at least one dose concurrent with Vitamin K 
were included in the study. Patients with a history of allergic reactions 
to cefoperazone/sulbactam and Vitamin K, coagulation laboratory data 
missing or presented with health problems that interfere the evaluation 
of bleeding conditions such as severe skin lesion, and patients presented 
with other bleeding conditions such as gastrointestinal bleeding and 
intracranial hemorrhage before receive cefoperazone/sulbactam were 
excluded from the study. Data were obtained by patient profiles review 
and clinical observation. Rate of bleeding events and coagulation 
laboratory abnormalities, risk factors affected coagulopathies, and 
drug-related problems were evaluated. The descriptive statistics 
including percentage and mean were used to determine demographic 
data and rate of events. Chi-square test was used to determine the 
association between coagulopathies and risk factors. The research 
protocol has been reviewed and accepted by ethical committees of 
Mahasarakham University and Mahasarakham Hospital.
RESULTS
There were 43 eligible patients enrolled in the study. Most patients 
were female (72.1%) and average age was 64.7 years old. Indication for 
the use of cefoperazone/sulbactam was pneumonia mostly, and most 
patients received this medication in high dose (81.4%). Demographic 
data of the patients are presented in Table 1.
There was one patient experienced gastrointestinal bleeding (2.3%). 
Prolonged prothrombin time occurred in 24 patients (55.8%) and 
prolonged activated partial thromboplastin time occurred in 8 patients 
(18.6%). Risk factors related to bleeding such as concurrent use of 
antithrombotics (warfarin, unfractionated heparin, enoxaparin, and 
aspirin), renal impairment, and hepatic impairment were not associated 
with coagulopathies (Table 2).
Drug-related problems occurred in 5 patients (11.6%) including no 
dose adjustment for cefoperazone/sulbactam in patients with renal 
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impairment (4.7%), warfarin and Vitamin K interaction (4.7%), and 
allergy to cefoperazone/sulbactam (2.3%).
DISCUSSION
There was still a lack of evidence to confirm clinical significant of 
cefoperazone/sulbactam-induced bleeding and coagulopathies. Our 
findings support this hypothesis because there were 2.32% of bleeding, 
55.8% prolonged prothrombin time, and 18.6% prolonged activated 
partial thromboplastin time occurred despite using Vitamin K to 
prevent. Risk factors that have been anticipated the coagulopathies in 
this study were concurrent use of antithrombotics, hepatic impairment, 
and renal impairment, but the results showed no statistically significant. 
Another risk factor proposed to be associated with coagulopathies was 
the quite high average age of patients (64.7 years). However, the trend 
of using this medication in Thailand is rising because of an emerging 
of multidrug-resistant pathogens such as Acinetobacter baumannii [5]. 
Because of some evidence has showed the efficacy of sulbactam in high 
dose against this bug, the use of cefoperazone/sulbactam in high-dose 
was followed which might increase the rate of coagulopathies [6-7]. The 
dose of cefoperazone/sulbactam over 3 g was used about 81.4% in this 
study and might lead to develop drug-related problem in the manner 
of dosage adjustment in 2 renal impairment patients which has been 
resolved by pharmacist interventions.
Other drug-related problems were drug interactions and drug allergy. 
Interactions between warfarin and Vitamin K became significant because 
of antagonism properties and need to be monitored closely. Drug allergy 
occurred as it was common side effects of beta-lactams, and the pharmacist 
had a role to manage this case by review timeline of medications use, 
assess the possibilities, and gave the intervention to physicians.
CONCLUSION
This study found bleeding and coagulopathies occurred in patients 
receiving cefoperazone/sulbactam despite concurrent use of Vitamin K. 
We support the use of Vitamin K to prevent these events, especially for 
high-risk patient such as elderly.
REFERENCES
1. Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, 
et al. Mechanism of cephalosporin-induced hypoprothrombinemia: 
Relation to cephalosporin side chain, Vitamin K metabolism, and 
vitamin K status. J Clin Pharmacol 1988;28:88-95.
Table 2: Risk factors related to bleeding or coagulopathies
Risk factors Exposed patients Unexposed patients Odds ratio (95% CI)
Total Outcome (%) Total Outcome (%)
Warfarin use 2 1 (50.0) 41 23 (56.1) 1.27 (0.1−21.8)
Heparin use 1 1 (100) 42 23 (54.7) 1.83 (1.4−2.4)
Enoxaparin use 1 1 (100) 42 23 (54.7) 1.83 (1.4−2.4)
Aspirin use 8 3 (37.5) 35 21 (60.0) 2.50 (0.5−12.1)
AST>200 IU/L 6 4 (66.7) 37 20 (54.1) 0.58 (0.1−3.6)
ALT>200 IU/L 4 2 (50.0) 39 22 (56.4) 1.29 (0.1−10.1)
SCr>2 mg/dl 11 8 (72.3) 32 16 (50) 0.37 (0.1−1.7)
AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, SCr: Serum creatinine, CI: Confidence interval
Table 1: Demographic data of eligible patients






Diabetes mellitus 12 (27.9)
Hypertension 24 (55.8)
Chronic kidney disease 12 (27.9)
Dyslipidemia 21 (48.8)
Gouty arthritis 1 (2.3)
Myocardial infarction 1 (2.3)
Heart failure 2 (4.65)
None 3 (7.0)
Abnormal aspartate aminotransferase (>200 IU/L) 6 (14.0)
Abnormal alanine aminotransferase (>200 IU/L) 4 (9.3)
Abnormal serum creatinine (>2 mg/dl) 11 (25.6)
Concurrent use of medication affected bleeding
Warfarin 2 (4.65)
Unfractionated heparin 1 (2.3)
Enoxaparin 1 (2.3)
Aspirin 8 (18.6)




Urinary tract infections 1 (2.3)
Intra-abdominal infections 1 (2.3)
Dose of cefoperazone/sulbactam (1:1 ratio)
≤3 g/day 8 (18.6)
>3 g/day 35 (81.4)
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